12:00 AM
 | 
Oct 08, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Exjade deferasirox regulatory update

FDA cancelled a Nov. 8 meeting of the Oncologic Drugs Advisory Committee (ODAC) that was scheduled to discuss an NDA from Celgene Corp. (NASDAQ:CELG, Summit, N.J.) for pomalidomide and an sNDA from Novartis for Exjade deferasirox. Celgene is seeking...

Read the full 184 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >